Literature DB >> 16711753

A combination of molecular dynamics and docking calculations to explore the binding mode of ADS-J1, a polyanionic compound endowed with anti-HIV-1 activity.

Fabrizio Manetti1, Cristina Tintori, Mercedes Armand-Ugón, Imma Clotet-Codina, Silvio Massa, Rino Ragno, José A Esté, Maurizio Botta.   

Abstract

The HIV-1 entry process is an important target for the design of new pharmaceuticals for the multidrug therapy of AIDS. A lot of polyanionic compounds, such as polysulfonated and polysulfated, are reported in the literature for their ability to block early stages of HIV-1 replication. Several studies have been performed to elucidate the mechanism of the anti-HIV-1 activity of sulfated polysaccharides and polyanions in general, including binding to cell surface CD4 and interfering with the gp120-coreceptor interaction. Here, we show molecular modeling investigations on ADS-J1, a polyanionic compound with anti-HIV activity that is able to interfere with gp120-coreceptor interactions. Agreeing with experimental data, computer simulations suggested that the V3 loop of gp120 was the preferential binding site for ADS-J1 onto HIV-1. Moreover, mutations induced by the inhibitor significantly changed the stereoelectronic properties of the gp120 surface, justifying a marked drop in the affinity of ADS-J1 toward an ADS-J1-resistant HIV-1 strain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16711753     DOI: 10.1021/ci050414h

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  2 in total

1.  ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation.

Authors:  Emmanuel González-Ortega; Maria-Pau Mena; Marc Permanyer; Ester Ballana; Bonaventura Clotet; José A Esté
Journal:  Antimicrob Agents Chemother       Date:  2010-07-19       Impact factor: 5.191

2.  Computer-Aided Approaches for Targeting HIVgp41.

Authors:  William J Allen; Robert C Rizzo
Journal:  Biology (Basel)       Date:  2012-08-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.